Evaluation of the efficacy and tolerance of intravenously administered imipenem/cilastatin in the treatment of septicaemia.
In an open study to determine the efficacy, safety and tolerance of intravenously administered imipenem/cilastatin (Tienam 500; Logos) in the treatment of septicaemia, 34 patients were given this thienamycin antibiotic in doses ranging from 1.5 g to 2 g daily for an average of 8.6 days (range 3-44 days). Based on clinical assessment, the study drug appeared to be effective in treating the septicaemia in 28 out of 34 patients and bacteriologically assessed eradication of the isolated pathogen was proven in 24 out of 34 patients. The drug appeared to be well tolerated in all but 4 patients, 3 of whom developed mild phlebitis and 1 a skin rash.